New York, New York – July 16, 2012 – ( Investorideas.com Newswire ) Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues a Q&A snapshot of two biotech companies taking aim at aggressive forms of cancer; Roche (SIX: RO, ROG; OTCQX: RHHBY) with its Herceptin® cancer drug and Sunshine Biopharma Inc. (OTCBB: SBFM) with its lead compound, Adva-27a.
The interview(s) gives investors insight into how a small biotech company, Sunshine Biopharma, plans to target the cancer drug market of the future with its technology and collaborations and the historical path of the largest biotech company in the world bringing Herceptin® to market, reaching sales of over $5 billion in 2010.
- Published: 16 July 2012
- Written by Investor Ideas